A Randomized, Double-Blind, Placebo-Controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PK/PD) of a Single Dose of GZR18 Injection in Obese/Overweight Subjects
Latest Information Update: 19 Aug 2024
At a glance
- Drugs GZR 18 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Gan&Lee Pharmaceuticals
Most Recent Events
- 19 Aug 2024 New trial record